- Home
- HRMY vs WNS Comparison
HRMY vs WNS Comparison
Compare HRMY & WNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- WNS
- Stock Information
- Founded
- HRMY 2017
- WNS 1996
- Country
- HRMY United States
- WNS India
- Employees
- HRMY N/A
- WNS N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- WNS Business Services
- Sector
- HRMY Health Care
- WNS Consumer Discretionary
- Exchange
- HRMY Nasdaq
- WNS Nasdaq
- Market Cap
- HRMY 2.0B
- WNS 2.5B
- IPO Year
- HRMY 2020
- WNS N/A
- Fundamental
- Price
- HRMY $31.70
- WNS $60.47
- Analyst Decision
- HRMY Strong Buy
- WNS Buy
- Analyst Count
- HRMY 9
- WNS 8
- Target Price
- HRMY $54.22
- WNS $63.00
- AVG Volume (30 Days)
- HRMY 627.2K
- WNS 688.6K
- Earning Date
- HRMY 08-05-2025
- WNS 07-17-2025
- Dividend Yield
- HRMY N/A
- WNS N/A
- EPS Growth
- HRMY 13.13
- WNS 24.08
- EPS
- HRMY 2.62
- WNS 3.71
- Revenue
- HRMY $744,852,000.00
- WNS $1,314,942,000.00
- Revenue This Year
- HRMY $20.10
- WNS $5.56
- Revenue Next Year
- HRMY $18.01
- WNS $9.37
- P/E Ratio
- HRMY $12.13
- WNS $16.29
- Revenue Growth
- HRMY 20.62
- WNS N/A
- 52 Week Low
- HRMY $26.47
- WNS $42.62
- 52 Week High
- HRMY $41.61
- WNS $72.11
- Technical
- Relative Strength Index (RSI)
- HRMY 38.57
- WNS 52.63
- Support Level
- HRMY $31.25
- WNS $56.23
- Resistance Level
- HRMY $32.46
- WNS $59.07
- Average True Range (ATR)
- HRMY 1.00
- WNS 2.02
- MACD
- HRMY -0.37
- WNS -0.05
- Stochastic Oscillator
- HRMY 11.69
- WNS 71.43
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically, the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), South Africa, and other countries.